Detalhe da pesquisa
1.
Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis.
N Engl J Med
; 388(12): 1080-1091, 2023 Mar 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-36920778
2.
Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial.
Lancet
; 402(10412): 1541-1551, 2023 10 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-37738999
3.
Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE).
Lancet
; 401(10370): 38-48, 2023 01 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36495881
4.
Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis.
N Engl J Med
; 384(12): 1101-1112, 2021 03 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-33761207
5.
Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3â years of treatment in randomized phase III trials.
Br J Dermatol
; 190(4): 477-485, 2024 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37950894
6.
Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials.
Br J Dermatol
; 190(5): 668-679, 2024 Apr 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-38226713
7.
Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: A subset analysis of two phase 3 randomized trials in plaque psoriasis.
J Am Acad Dermatol
; 90(4): 775-782, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38122848
8.
Atopic dermatitis is associated with an increased risk of cardiovascular diseases: A large-scale, propensity-matched US-based retrospective study.
Clin Exp Dermatol
; 2024 May 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38703379
9.
Are interleukin 17 and interleukin 23 inhibitors associated with malignancies?-Insights from an international population-based study.
J Eur Acad Dermatol Venereol
; 38(2): 315-324, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37730962
10.
Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2).
J Eur Acad Dermatol Venereol
; 2024 Mar 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38451052
11.
[Immune-mediated inflammatory diseases in Germany : A cross-sectional analysis of comorbidities and pharmacotherapy]. / Chronische Entzündungserkrankungen in Deutschland : Eine Querschnittanalyse über Begleiterkrankungen und Arzneimitteleinsatz.
Z Rheumatol
; 83(3): 200-209, 2024 Apr.
Artigo
em Alemão
| MEDLINE | ID: mdl-36600054
12.
Safety of guselkumab treatment for up to 5â years in patients with moderate-to-severe psoriasis: pooled analyses across seven clinical trials with more than 8600 patient-years of exposure.
Br J Dermatol
; 189(1): 42-52, 2023 07 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37022762
13.
Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial.
Br J Dermatol
; 188(1): 22-31, 2023 01 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-36689515
14.
Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial.
J Am Acad Dermatol
; 89(3): 486-495, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37182701
15.
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial.
J Am Acad Dermatol
; 88(1): 40-51, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36115523
16.
Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: A randomized phase 2b clinical trial.
J Am Acad Dermatol
; 88(2): 395-403, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36370907
17.
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial.
J Am Acad Dermatol
; 88(1): 29-39, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35820547
18.
Evaluating the risk of infections under interleukin 23 and interleukin 17 inhibitors relative to tumour necrosis factor inhibitors - A population-based study.
J Eur Acad Dermatol Venereol
; 37(11): 2319-2326, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37466275
19.
Comparison of different skin care regimens in patients with moderate to severe atopic dermatitis receiving systemic treatment: A randomized controlled trial.
J Eur Acad Dermatol Venereol
; 37 Suppl 5: 18-26, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37092275
20.
Upadacitinib treatment withdrawal and retreatment in patients with moderate-to-severe atopic dermatitis: Results from a phase 2b, randomized, controlled trial.
J Eur Acad Dermatol Venereol
; 37(12): 2558-2568, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37528500